Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

BMS/bluebird bio resubmit FDA application for myeloma CAR-T

Novel CAR-T therapy targets heavily pre-treated myeloma

- PMLiVE

Post-COVID-19 behaviour – the new normal or nothing new?

By Joe Marshall

- PMLiVE

The power of remote personal interactions: COVID-19 pandemic and the increasing role of remote engagement

By Karen Ticozzi and Liz Murray

- PMLiVE

AZ strengthens Daiichi Sankyo partnership with new ADC deal

Deal for experimental antibody drug conjugate could reach $6bn

- PMLiVE

Moderna looks to price COVID-19 vaccine at $50-$60 per course

Shines spotlight on pricing strategies for potential vaccines

- PMLiVE

UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

UK adds to its arsenal of potential vaccine candidates

- PMLiVE

Roche’s Actemra fails in late-stage severe COVID-19 study

Anti-inflammatory drug unable to improve clinical status of hospitalised patients

Understanding COVID-19 and varying responses across the globe

At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global...

Blue Latitude Health

- PMLiVE

Moderna’s COVID-19 vaccine enters pivotal phase 3 trial

Large-scale study will evaluate vaccine in 30,000 participants

- PMLiVE

Pfizer, BioNTech identify and advance lead COVID-19 vaccine candidate

Companies pick the most promising candidate to take into phase 2/3

AstraZeneca AZ

Emergent inks $174m deal with AstraZeneca to manufacture COVID-19 vaccine

Follows initial deal agreed in June

Persuasive technology: designing behaviour change initiatives for digital

By Michelle Kelly

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links